The Interventional Effects of Tubson-2 Decoction on Ovariectomized Rats as Determined by a Combination of Network Pharmacology and Metabolomics

Fan Yang†, Xin Dong†, Feixiang Ma†, Feng Xu‡, Jie Liu†, Jingkun Lu†, Chunyan Li†, Ren Bu† and Peifeng Xue*†

1 Department of Pharmacy, Inner Mongolia Medical University, Hohhot, China, 2 State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China

Post-menopausal osteoporosis (PMOP) is associated with estrogen deficiency and worldwide, is becoming increasingly more prevalent in aging women. Various anti-PMOP drugs have been developed to reduce the burden of PMOP; generally, these drugs are efficacious, but with some adverse side effects. Tubson-2 decoction (TBD), a popular traditional Mongolian medicine, has been used to treat PMOP for centuries. However, the precise mechanisms underlying the action of TBD on PMOP have yet to be fully elucidated. Herein, we combined network pharmacology with untargeted metabolomics to identify the key targets and metabolic pathways associated with the interventional effects of TBD on ovariectomized (OVX) rats. Furthermore, we investigated the bone histomorphometry of eight different groups of rats to evaluate the therapeutic effect of TBD. First, we established a TBD-target/PMOP network via network pharmacology; this network identified three key protein targets—vitamin D receptor (VDR), cytochrome P450 19A1 (CYP19A1), and 11β-hydroxysteroid dehydrogenase type 1 (HSD11B1). Morphological analysis showed that severe impairment of the bone micro-architecture in OVX rats could be improved by TBD administration. The TBD-treated rats had a significantly lower bone surface-to-tissue volume (BS/TV) and a significantly smaller trabecular separation (Tb·Sp.) (P<0.05) than the OVX rats; in contrast, bone volume fraction (BVF), trabecular thickness (Tb·Th.), trabecular number (Tb·N.), and bone mineral density (BMD) were significantly higher in the TBD-treated rats (P<0.05). Multivariate and univariate analysis showed that OVX resulted in significant alterations in the concentrations of 105 metabolites and 11 metabolic pathways (P<0.05); in addition, 26 potential biomarkers were identified to investigate the progression of PMOP. Network pharmacology showed that major alterations in vitamin B6 metabolism were associated with the VDR target. Next, we validated the three crucial targets (VDR [P<0.01], HSD11B1 [P<0.01], and CYP19A1 [P<0.05]) by enzyme-linked immunosorbent assays (ELISAs) and demonstrated that the levels of these targets were elevated in the

OPEN ACCESS

Edited by: Yan Xu, Cleveland State University, United States

Reviewed by: Man Sau Wong, Hong Kong Polytechnic University, Hong Kong; Yun-lun Li, Shandong University of Traditional Chinese Medicine, China

*Correspondence: Peifeng Xue Xpfdc153@163.com
†These authors have contributed equally to this work

Specialty section: This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology

Received: 10 July 2020
Accepted: 09 September 2020
Published: 14 October 2020

Citation: Yang F, Dong X, Ma F, Xu F, Liu J, Lu J, Li C, Bu R and Xue P (2020) The Interventional Effects of Tubson-2 Decoction on Ovariectomized Rats as Determined by a Combination of Network Pharmacology and Metabolomics. Front. Pharmacol. 11:581991. doi: 10.3389/fphar.2020.581991
INTRODUCTION

Osteoporosis is a systemic bone disease that results in alterations in the microscopic architecture of the bone and a reduction in bone mass (Zou et al., 2020); collectively, these effects result in an impairment of bone quality. Post-menopausal osteoporosis (PMOP) is a global public health issue and has become a significant cause for concern for middle-aged and elderly women (Alexandre and Vico, 2011). Estrogen deficiency is known to be one of the most important mechanisms underlying PMOP and usually occurs 5 to 10 years after menopause (Li et al., 2020). Research studies have also shown that osteoclastic activity exceeds osteoblastic activity after menopause, thus leading to an increase in bone resorption. In turn, these events cause an overall reduction in bone mass reduction and a concomitant increase in skeletal fragility (Gambacciani et al., 2019). Over the last few decades, a considerable body of evidence has accumulated in support of the fact that estrogen prevents bone loss by blocking the production of proinflammatory cytokines by the bone marrow and bone cells. Thus, estrogen replacement therapy remains the gold standard for treating PMOP (Jiang, 2018). However, over the long-term, estrogen replacement therapy is associated with a range of side effects, including pain in the ovaries and endometrium and invasive breast cancer (Komm et al., 2015). Consequently, there is an urgent need to identify novel treatment modalities that are effective but with fewer side effects than existing therapies. Traditional Chinese medicine (TCM), along with other forms of ethnic medicines, has emerged as promising candidates for the treatment of complex diseases because these forms of medicine contain multiple components that act on multiple targets. Many researchers have highlighted the fact that many herbs, and prescriptions created from these herbs, can exert estrogen-like action, including Eucommia ulmoides Oliver (EC) (Zhang et al., 2012), Epimedium brevicornu Maxim (Liu H. et al., 2018), Achyranthes bidentata (Zhang M. et al., 2018), and Echinops latifolius Tausch (ELT) (Wang et al., 2020). Considering that these herbs, and their prescriptions, are known to have good anti-osteoporosis effects, it follows that TCM (Li et al., 2018), and other ethnic medicines, may represent a natural drug resource for screening new drugs for the treatment of PMOP.

Tubson-2 (TBD), also known as Erwei Duzhong Decoction, is composed of ELT and EC. This is the basic prescription of Mongolian medicine for treating osteoporosis, recorded in Golden Cabinet of Mongolian Medicine (Zhan, 1977). In a previous study, researchers (Liu, 2016) applied this prescription to 60 patients with PMOP and reported a total effective rate of 90%. In addition, the ameliorating effect of TBD on estrogen receptors, inorganic elements, bone density, bone biomechanics, and bone metabolism, in ovariectomized (O VX) rats have also been investigated in previous research studies (Liu, 2016). Interestingly, ELT was shown to be able to prevent PMOP by activating the estrogen receptor (ER)/protein kinase B (AKT)/extracellular-signal regulated kinase (ERK) pathway in bone marrow derived mesenchymal stem cells (BMSCs) (Liu Y. et al., 2018), and that the main components of ELT (such as chlorogenic acid and its derivatives) were closely related to oxidative balance in femoral tissue (Han et al., 2017). Moreover, the active compound in EC is known to be a powerful inhibitor of adipogenesis and an enhancer of osteoblastogenesis (Tan et al., 2014). Although the substances that make up ELT and EC have been shown to exert good effects against osteoporosis, the specific mechanisms that underlie the effect of TBD on PMOP have yet to be fully elucidated. However, the complexity of TBD makes its very challenging to investigate its specific mechanism of action. Unlike traditional western medicine, it is not possible to use monomers to perform pharmacodynamic tests with TBD.

Network pharmacology is a new discipline that allows researchers to discover the mechanisms underlying the effects of drug combinations based on multidisciplinary theories such as systems biology and multidirectional pharmacology (Hao and Xiao, 2014). Furthermore, network pharmacology allows us to construct a ‘disease-targets-drug’ network in order to elucidate the mechanisms of action for specific drugs. Metabolomics is considered the latest “omics” science and involves the comprehensive and systematic analysis of small molecular metabolites from tissues, cells, or biological fluids (Johnson et al., 2016). The composition and concentration of metabolites may change with disease progression; this, in turn, will help us to screen potential biomarkers or targeted therapeutic pathways that are closely related to the disease (Lv et al., 2016). Currently, the overall concept of network pharmacology and metabolomics concurs with the ‘multi-component and multi-target’ theory of traditional herbal medicines that is used widely to discover the mechanisms underlying the action of traditional herbal medicines (Zhang et al., 2020).

In the present study, we used a combination of network pharmacology and non-targeted metabolomics to identify and characterize the key targets and metabolic pathways associated with the interventional effects of TBD on PMOP. To verify the efficacy of TBD on PMOP, we created an OVX rat model to mimic the physiological characteristics of menopausal women. First, we established a TBD-target/PMOP network via network pharmacology; this network was then used to identify key
protein targets. Next, we analyzed relevant metabolites and metabolic pathways by performing ultra-high performance liquid chromatography mass spectrometry (UHPLC-MS) on serum samples acquired from treated and non-treated rats. Finally, we validated the crucial targets of shared pathways identified by network pharmacology and metabolomics to identify the main interventional effects of TBD on OVX rats. We believe that this approach could significantly enhance our understanding of the mechanisms underlying the effect of TBD on PMOP and thus help to promote its clinical application.

MATERIALS AND METHODS

Chemicals and Reagents

Echinops latifolius Tausch (ELT) was collected from Wu Chuan (Hohhot, China) and Eucommia ulmoides Oliv. (EC) was purchased from Bozhou Pharmaceutical Co. Ltd. (Anhui, China). Choral hydrate, combined estrogen tablets, Gushukang granules, and saline, were purchased from Ze Sheng Biotechnology Company (Hohhot, China). Methanol and formic acid (MS grade) were acquired from Fisher Scientific Corporation (Loughborough, UK). Ultra-high purity water (18.2 MΩ) was obtained from an ALH-600-U purification system (Chongqing, China). Enzyme-linked immunosorbent assay (ELISA) kits for the vitamin D receptor (VDR), cytochrome P450 19A1 (CYP19A1), 11β-hydroxysteroid dehydrogenase type 1 (HSD11B1) were obtained from Hua Lian Biotechnology Institute (Wuhan, China).

Instrumentation

The research described herein utilized the following equipment: a high resolution in-vivo X-ray microtomograph (SkyScan 1176, Bruker, Germany), a digital microscope (MOTICBA210, Motic, China), an ultrapure water system (ALH-600-U, China), a Thermo Scientific Q Exactive Quadrupole-Orbitrap Mass Spectrometer System (Thermo Fisher Scientific Inc, Grand Island, NY, USA), a rotary evaporator (EYELA n-1100, Shanghai Alang Instruments Co., China), and a microplate reader (Beijing Prolong New Technology Co., China).

Plant Materials and Preparation of Tubson-2 Decoction

Herbal materials of ELT were collected from Wu Chuan (Hohhot, China, GPS co-ordinates of the plant collection site is 41.1206962700, 111.4084477500) in early autumn 2019 and identified by Professor PX (Department of Natural Medicinal Chemistry, Inner Mongolia Medical University) with the voucher specimen (#20190715) collected in the herbarium of Inner Mongolia Medical University. EC herbal materials were purchased from Bozhou Pharmaceutical Co. Ltd. (Anhui, China) and morphologically authenticated by PX. The voucher specimens were also deposited in the herbarium of Inner Mongolia Medical University (#20190822).

The final preparation of TBD was carried out as described in our previous paper. In brief, two herbal materials were ground into powder and screened over 50 mm sieve before use. Equal amounts of ELT and EC powders were mixed and then were soaked with ultrapure water at a material-liquid ratio of 1:10 (g/ml) for half an hour before being hot reflux extraction. Subsequently, these powders were refluxed at 100°C twice (for 30 min each time), and then filtered through 180 mm sieve. Following filtration, the filtrate was collected, concentrated, and freeze-dried to obtain a lyophilized TBD powder. Powders were stored in a refrigerator at 4°C and dissolved in an appropriate amount of distilled water prior to use. The chemical profile of TBD was achieved by UPLC-MS/MS (Supporting Information Figure S1). The content of sixteen active ingredients in TBD sample was list as Supporting Information Table S1.

Establishment of an OVX Rat Model

Twelve-week-old female Wistar rats, 250–270 g in weight, were purchased from the Laboratory Animal Institute of Inner Mongolia Medical University (Hohhot, China). All animal procedures were approved by the Animal Ethics Committee of Inner Mongolia Medical University (Reference: SCXK2015-0001). Rats were kept in a barrier system with controlled temperature (25–28°C) and humidity (50%–60%) and a light-dark cycle of 12 h per day. After 7-day of acclimatization, 48 rats were equally randomized to 8 groups (6 rats per group), including a blank group, a sham group, an OVX group, a positive control drug group (Gushukang-treated group and an estrogen-treated group), a TBD high dose group, a TBD middle dose group, and a TBD low dose group. All rats except those in the blank group were injected with 10% chloral hydrate solution (0.5 ml/100 g body weight) prior to surgery. Bilateral laparotomy was conducted in the sham group (n=6) while bilateral ovariectomy was carried out in the model group (n=36, six rats were regarded as the OVX group, while the remaining rats were allocated to drug-treatment groups). Seven days after surgery, all rats were subjected to keratinization experiments involving the vaginal epithelium; vaginal smears were then performed once a day for 5 consecutive days. The morphology and staining of the cells contained within vaginal smears were observed by optical microscopy at a magnification of 100×. Results showed that the estrus cycle appeared alternately in the blank group (Figures 1A–C), while an estrus interval appeared in the model group (Figure 1D) five consecutive days of vaginal smear to tips for successful modeling.

The low dose group was given 237.5 mg·kg⁻¹·d⁻¹ of lyophilized TBD (equivalent to 1.05 g·kg⁻¹·d⁻¹ of raw medicine), the middle dose group was given 475 mg·kg⁻¹·d⁻¹ (equivalent to 2.1 g·kg⁻¹·d⁻¹ of raw medicine), and the high dose was given 950 mg·Kg⁻¹·d⁻¹ (equivalent to 4.2 g·kg⁻¹·d⁻¹ of raw medicine). The Gushukang-treated group was given Gushukang granules (105.1 mg·kg⁻¹·d⁻¹) while estrogen-treated group was given combined estrogen tablets (0.065 mg·kg⁻¹·d⁻¹). During the same period, the blank group, sham group, and OVX group, were given the same volume of 0.9% saline daily. After 8 weeks of gavage treatment, we anesthetized all animals with 10% chloral hydrate solution and acquired cardiac blood samples. Serum was separated by centrifugation at 3,500 rpm for 10 min at 4°C and frozen at -80°C to await metabolomics analysis. We also removed the left tibia...
from each animal and fixed these samples in formalin to await analysis.

**Analysis of Bone Mineral Density and Trabecular Micro-Architecture**

X-ray microtomography was used to analyze bone mineral density and trabecular micro-architecture. All tibias were fixed with 70% ethanol and subjected to X-ray microtomography with an isotropic voxel size of 10 μm. Tomographic images were acquired at an integration time of 250 ms with 500 projections over the full 360° rotation. Three dimensional reconstructions were generated with the following parameters: smoothing was set as 3; ring artifacts reduction was set to 5; and beam hardening correction was set to 30%. Bone volume fraction (BVF), bone surface to tissue volume (BS/TV), trabecular thickness (Tb·Th.), trabecular number (Tb·N.), trabecular separation (Tb·Sp.), and bone mineral density (BMD), were all determined by analyzing a specific region of interest (ROI) that was chosen by setting the same coordinates in the tibial growth plate for each sample.

**Network Pharmacology Analysis**

**Compound Data Acquisition**

Details relating to the compounds identified in ELT and EC were obtained by searching the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP; http://tcmspw.com/tcmsp.php) (Ru et al., 2014), the Encyclopedia of Traditional Chinese Medicine (ETCM; http://www.nrc.ac.cn:9090/ETCM/) (Xu et al., 2019), and existing literature (Wang et al., 2020). We also added some additional compounds, as determined by the fingerprint we created for TBD in a previous study (Guo et al., 2020).

**Target Fishing**

We used a systemic approach that was based on information integration and text-mining to identify the targets of TBD. Targets were retrieved from Swiss Target Prediction (http://www.swisstargetprediction.ch) (Gfeller et al., 2014) and Superpred Webserver (http://prediction.charite.de/) (Nickel et al., 2014) software. The SMILE structure of each component was then introduced into Swiss Target Prediction with a probability threshold of 0.6–1. All known and predicted targets were then selected from the Superpred Webserver. Next, the targets that were related to PMOP were acquired from Drugbank (http://www.drugbank.ca/atc) (Wishart et al., 2018). We then constructed a compound-target network and then removed the components of TBD that were not connected with PMOP targets.

**Construction of a Protein-Protein Interactions (PPI) Network Related to PMOP**

The String database (https://string-db.org/Version 10.5) is a database that is commonly used to analyze known and predicted protein-protein interactions. The common targets of PMOP, along with the active ingredients of TBD, were introduced into the database for protein-protein interaction...
(PPI) analysis and the species set to “human.” We then imported node 1, node 2, and comprehensive scoring information, into Cytoscape 3.0 software to create a PPI network map.

**Determination of Key Targets**

By filtering common targets, it was possible to identify the specific pathways of the targets via the DAVID database (https://david.ncifcrf.gov/). Next, using the potential targets of TBD for PMOP, we performed enrichment analysis of biological processes using the CLUE GO plugin in Cytoscape software. We then considered this data along with the rankings for biological functions and pathways and identified important pathways. Next, we ranked the genes associated with the identified pathways in terms of frequency and integrated the target data into the PPI network diagram. Finally, we defined the key targets of TBD in PMOP that would be subsequently assayed quantitatively by enzyme-linked immunosorbent assays (ELISAs).

**Metabolomics Analysis**

**Preparation of Serum Samples and Quality Control (QC) Samples**

Serum samples were thawed at 4°C prior to analysis. Then, 200 µl of each serum sample was mixed with 600 µl of methanol and vortexed for 3 min. Subsequently, the samples were centrifuged at 15,000 rpm for 10 min at 4°C. Supernatants were then transferred to new microcentrifuge tubes and dried in a vacuum dryer. Finally, the samples were dissolved in 200 µl of methanol for analysis.

Quality control (QC) samples were created by pooling serum samples from each analysis sequence. QC samples were analyzed after every 10 samples. This practice ensured that our analysis was accurate and consistent.

**UHPLC-MS Conditions**

UHPLC-MS analysis was performed on a Thermo Q-Exactive-MS (Thermo, USA). Chromatographic separations were performed on a Waters ACQUITY UPLC HSS T3 column (2.1×50 mm, 1.8 µm) at 35°C, and the flow rate was set to 0.4 ml/min. The mobile phase was formed by MS-grade methanol (A) and water containing 0.1% formic acid (B). The gradient program was set to the following parameters: 0–1.7 min, 5%–10% A; 1.7–3.0 min, 15%–17% A; 3.0–3.3 min, 17% A; 3.3–8.0 min, 17%–25% A; 8.0–9.7 min, 25%–30% A; 9.7–10.6 min, 30%–35% A; 10.6–14.1 min, 35%–55% A, 14.1–14.6 min, 55% A; 14.6–15.1 min, 55%–100% A; 15.1–17.0 min, 100% A; 17.0–18.1 min, 100%–5% A; 18.1–20 min, 5% A. For each sample, we injected 5 µl for analysis.

Q-Exactive-MS analysis was performed in full scan/dd ms² mode. Spray voltage was set to 4 kV for positive ion mode and 3.2 kV for negative ion mode. The sheath gas flow rate was 40 L/min for positive ion mode and 35 L/min for negative ion mode. The auxiliary gas flow was 2 L/min for both of the ion mode sat 350°C. The capillary temperature was 300 V for both two ion modes. Data were collected in centroid mode and the mass range was 100–1,100 m/z.

**Data Processing and Statistical Analysis**

Original data files were independently processed by Compound Discoverer (CD)™ 2.0 software for peak alignment, peak filter, peak extraction, and automatic integration. The minimum peak intensity for component extraction was 2×10⁶ and the mass tolerance was 10 ppm. The retention time window was 1 min and the signal-to-noise ratio was 3. CD software was then used for spectral comparison, grouping, compound detection, and metabolite identification. We were then able to create multidimensional peak tables containing prediction formulas, accurate mass data, retention times, peak areas, and mzCloud results. The multi-dimensional peak tables acquired in positive and negative ion mode were processed separately and transferred into a Microsoft Excel file which was subsequently imported into SIMCA-P (version 14.1, Umetrics, Sweden) Performing principal component analysis (PCA) was then performed to identify the overall metabolic profile for each group of samples. Supervised partial least squares discriminant analysis (PLS-DA) was then applied to compare distinguishing markers between the OVX group and the sham group. The fitness and predictive ability of the model were then verified according to R2 and Q2 values in cross-validation and permutation tests, respectively. We then identified potential biomarkers as metabolites with P < 0.05 and variable importance plot (VIP) > 1.

Potential biomarkers were then matched with structural data acquired from the Human Metabolome Database (HMDB) (http://www.hmdb.ca/) and mzCloud (https://www.mzcloud.org/). Pathway enrichment analysis was then performed for the identified biomarkers using MetaboAnalyst (http://www.metaboanalyst.ca/).

**Analysis of Biochemical Indicators**

Blood samples were collected from all rats at sacrifice, as described earlier. The serum levels of VDR, HSD11B1, and CYP19A1, were then determined by enzyme-linked immunosorbent assays (ELISAs) in accordance with the manufacturer’s instructions.

**Statistical Analysis**

Data relating to BVF, BS/TV, Tb-N., Tb-Sp., Tb-Th., BMD, CYP19A1, VDR, and HSD11B1, are described as the mean ± standard deviation (SD). The student’s unpaired t test was performed with SPSS 19.0 software and a P value ≤ 0.05 was regarded as statistically significant.

**RESULTS**

**TBD Improved Ovariectomy-Induced Bone Loss and Deleterious Changes in the Trabecular Micro-Architecture**

Analysis of vaginal smears from our experimental rats proved that the PMOP model had been successfully established by ovariectomy. Three dimensional microtomographic analyses allowed us to gather additional architectural, cortical, and trabecular, information from the tibias of experimental rats. We found that the OVX group showed significant changes in both BMD and trabecular micro-architecture. As shown in Figure 2C, the bone microstructure of the tibia in the OVX group exhibited severe damage. Moreover, the trabecular region in the OVX rats appeared to be small, thin and
sparse. Analysis also revealed that there was a significant reduction in Tb-N. \( P=0.003 \), BVF \( P=0.011 \), BMD \( P=0.008 \), and BS/TV \( P=0.001 \), along with a significant increase in Tb-Sp. \( P=0.000 \) in the OVX group (Figures 3A–F).

One striking observation arising from our analysis of bone mineral density and trabecular micro-architecture was the existence of a severe reversion in bone loss in the treatment groups (Figures 2A–H). All treatment groups showed a remarkable improvement in trabecular micro-architecture, with a slightly dilated medullary cavity and a slightly disordered trabecular arrangement (Figures 2D–H). The trabecular morphological parameters were turned over in these drug-treated groups as shown in Figures 3A–F. Compared with the OVX group, the drug-treatment groups showed significant elevations of Tb-N. \( P<0.05 \), BVF \( P<0.05 \), BMD \( P<0.05 \), and BS/TV \( P<0.05 \), and a reduction of Tb-Sp. \( P<0.05 \). There was only a marginal and non-significant difference in the estimated trabecular morphological parameters when compared between different drug-treatment groups. This data demonstrated that TBD has similar effects in OVX rats as the positive drug. However, the effect of TBD on these indicators did not show a dose-dependent effect.

**VDR, HSD11B1, and CYP19A1 Were Crucial Targets in the Interventionsal Effects of TBD on OVX Rats**

Following the screening of compound data, we identified 195 compounds in TBD, of which 28 were unique to ELT, 163 were unique to EC, and 4 were common to both herbs. Because the oral bioavailability (OB) and drug-likeness (DL) values for most compounds in EC and ELT were low or unknown, we were not able to apply these values for compound screening. We therefore considered all compounds with known targets as the active ingredients of EC and ELT. In total, 62 compounds had known targets; these were considered as the active ingredients of TBD.

Following the removal of duplicates, we identified a total of 2,251 targets for TBD. In total, we identified 1,412 targets for the active ingredients of EC, 509 targets for the active ingredients of ELT, and 330 targets for the targets shared by EC and ELT. All compound targets were retrieved from Swiss Target Prediction software and the Superpred Webserver. We also identified 581 gene targets that were associated with PMOP via the use of Drugbank. After comparing the targets that were associated with both TBD and PMOP, we identified 89 potential targets for TBD against PMOP. These potential targets were entered into the String database (set to human and a high confidence level of 0.7). Node 1 and node 2 were then imported into Cytoscape software to allow us to create an interaction network (Figure 4). The nodes shown in Figure 4 graph represent the targets while the edges represent associations between different proteins. The color and size of the nodes reflect the degree value for each protein target: the larger and darker the node, the greater the degree value. As shown in Figure 4, the target interaction network featured 89 nodes and 626 edges. According to degree
FIGURE 3  |  (A) Comparison of bone mineral density (BMD) in eight groups; (B) Comparison of Tb•Th in eight groups; (C) Comparison of Tb•Sp in eight groups; (D) Comparison of bone volume fraction (BVF) in eight groups; (E) Comparison of Tb•N in eight groups; (F) Comparison of BS/TV in eight groups. Values were expressed as the mean ± SD; n = 6. *p < 0.05, **p < 0.01 compared with blank group. *p < 0.05, **p < 0.01 compared with OVX group.

FIGURE 4  |  Protein interaction network of Tubson-2 decoction (TBD) against post-menopausal osteoporosis (PMOP). The nodes in the graph represent targets, while the edges represent the association between proteins. And the node size represented degree value. The larger the node, the larger the degree value.
values, the key targets for TBD against PMOP were CYP19A1, HSD11B1, VDR, and albumin (ALB).

GLUE GO analysis identified the top biological features of our interaction network as hormone metabolic process, steroid metabolic process, and oxidoreductase process. We then calculated the gene frequencies for the key target genes in these three biological pathways. Analysis showed that VDR, CYP19A1 and beta-2 adrenergic receptor (ADRB2) appeared eight times; tyrosine-protein phosphatase non-receptor type (PTPN), estradiol 17-beta-dehydrogenase 1 (HSD17B1), and ethylene-responsive transcription factor ESR1 (ESR1) appeared seven times; and HSD11B1 appeared six times. By combining these results with the PPI data, we found that CYP19A1, HSD11B1, and VDR were the most important potential targets for TBD when used to treat PMOP.

**Metabolomics Analysis Showed That 26 Potential Biomarkers Were Involved in OVX-Induced Osteoporosis and Regulated by TBD**

As shown in the PCA score plot (Figures 5A, B), the analysis of QC samples showed good reproducibility and reliability. PCA showed that the dataset derived from the OVX group was separated from the data derived from the other groups. The widespread distribution of data following PCA was likely to be caused by individual differences in rats and/or the timing of sampling. To exclude the effect of potential confounding variables that were not related to the group differences, and to evaluate the statistical significance of these effects, we applied PLS-DA analysis (Figures 5C, D). The results of this analysis were highly encouraging as the discrimination model could readily differentiate between the eight groups. Although the distribution of pre-cachexia overlapped with the OVX and estrogen groups, these models showed appropriate goodness-of-fit values with high cross-validation predictability, with cumulative R2Y values of 1.000 and cumulative Q2 values of 0.977 in the positive mode, and R2Y value of 0.959 and a cumulative Q2 value of 0.541 in the negative mode (Table 1), indicating reliable differentiation between the groups.

In order to identify distinct biomarkers that may be associated with TBD treat OVX-induced osteoporosis among a dataset featuring thousands of variables, we conducted pairwise comparisons between the OVX and TBD medium-treated groups (Figures 6A, B). Validation analysis was satisfactory with regards to group classification, with a cumulative R2Y value of 0.999 and a cumulative Q2 value of 0.978 in the positive mode, and a cumulative R2Y value of 0.997 and a cumulative Q2 value of 0.935 in the negative mode (Table 1). Permutation tests for the TBD medium-treated groups and OVX group are shown in Figures 6C, D. After filtering with VIP values, and results arising from the Student’s t test, we identified 105 metabolites as potential biomarkers (82 metabolites from the positive ion mode and 23 metabolites from the negative ion mode). Next, we used HMDB and the mzCloud online database to identify these potential biomarkers. By considering the metabolites that overlapped each pairwise comparison, we identified a total of 26 putative biomarkers (Table 2). The potential differential metabolites were identified by standard,
ferulic acid, 350 its parent ion is [M-H]-: 193.005063, the main product ion fragments are (m/z): 134.03546, 351 149.06041, 178.00696, and the retention time is 11.45 min. This is consistent with our results and further confirms the reliability of the ferulic acid test results.

Metabolomic Analysis Identified Vitamin B6 Metabolism as the Key Pathway in OVX-Induced Osteoporosis and Could Be Regulated by Tubson-2

Next, we pooled the metabolites that showed alterations in rat serum and identified a total of 26 putative metabolites for analysis. The fold-changes of these metabolites in the OVX, sham, and medium-dose-treated groups are shown in Table 2. Pathway analysis, carried out using MetaboAnalyst (http://www.metaboanalyst.ca/), revealed the detailed impacts of OVX-related alterations in metabolic networks (Figure 7A). To investigate the most influential metabolic pathway, we set the following threshold values: -log (P) values >1.5 and pathway impact >0.1. Three metabolic pathways were defined as being disturbed in the serum profiles of rats with TBD treated OVX-induced osteoporosis: vitamin B6 metabolism, phenylalanine metabolism, phenylalanine, and tyrosine and tryptophan biosynthesis. Based on the biomarkers that were potentially responsible for TBD treatment, we then used the Kyoto Gene and Genome Encyclopedia database (KEGG (http://www.genome.ad.jp/kegg/), and the human metabolism database (http://www.hmdb.ca/), to create a metabolic network for metabolic pathways that were altered by TBD treated OVX (Figure 7B).

### TABLE 1 | Summary of partial least squares discriminant analysis (PLS-DA) model parameters for evaluating model quality by 200 permutation tests of corresponding validation plots.

| Ion mode         | A | R²X | R²Y | Q²(cum) | R² intercepts | Q² intercepts |
|------------------|---|-----|-----|---------|---------------|---------------|
| OVX vs Sham      |   |     |     |         |               |               |
| Positive mode    | 2 | 0.413 | 0.998 | 0.939 | 0.921 | -0.237 |
| Negative mode    | 2 | 0.361 | 0.956 | 0.517 | 0.88 | -0.0204 |
| OVX vs Medium-treated |   |     |     |         |               |               |
| Positive mode    | 2 | 0.620 | 0.999 | 0.978 | 0.802 | -0.0681 |
| Negative mode    | 2 | 0.420 | 0.997 | 0.935 | 0.895 | -0.0716 |
| OVX VS Estrogen-treated |   |     |     |         |               |               |
| Positive mode    | 2 | 0.552 | 1.000 | 0.977 | 0.869 | -0.0498 |
| Negative mode    | 2 | 0.313 | 0.959 | 0.541 | 0.914 | -0.0144 |

A was number of components.
Target Validation Was Performed by ELISA Assay

We used network pharmacology and metabolomics to identify the crucial targets for TBD in the treatment of PMOP; the most important targets were VDR, HSD11B1, and CYP19A1. We then used ELISA kits to validate the levels of these crucial targets in samples of rat sera. As shown in Figure 8, the concentrations of VDR, HSD11B1, and CYP19A1 were elevated in the OVX group, thus presenting the inhibition of these cytokines. The serum levels of VDR and CYP19A1 were reduced following the administration of TBD, suggesting that TBD is able to treat OVX-induced osteoporosis by ameliorating the levels of VDR and CYP19A1.

| NO. | Metabolite | Formula | Adduct | Accurate Mass (m/z) measured | Error*(ppm) | RT(min) | VIP (OVX)/(Sham) (Medium treated)/(OVX) |
|-----|------------|---------|--------|------------------------------|-------------|--------|---------------------------------------|
| 1   | Monobutyl phthalate | C12H14O4 | [M-H]- | 223.0964 | 222.0888 | 1.77 | 1.90 | ↓ | ↓ | 
| 2   | 4-Methylhippuric acid | C9H12NO3 | [M-H]- | 158.0822 | 159.0878 | 6.36 | 4.79 | 1.48 | ↓ | ↓ | 
| 3   | N-Isovalerylglycine | C6H13NO3 | [M-H]- | 231.0775 | 232.0836 | 4.35 | 8.02 | 1.46 | ↓ | ↓ | 
| 4   | Phenobarbital | C12H12N2O3 | [M-H]- | 188.0706 | 187.0631 | 5.35 | 13.48 | 1.45 | ↓ | ↓ | 
| 5   | Indole-3-acrylic acid | C12H16O5 | [M-H]- | 295.2279 | 296.2346 | 3.41 | 18.10 | 1.44 | ↓ | ↓ | 
| 6   | N-Formylmethionine | C9H11NO2S | [M-H]- | 176.0387 | 177.0445 | 5.71 | 1.72 | 1.42 | ↓ | ↓ | 
| 7   | 3-Hydroxybutyric acid | C4H8O3 | [M-H]- | 103.0400 | 104.0456 | 9.75 | 0.82 | 1.36 | ↓ | ↓ | 
| 8   | 12-Hydroxydecanedioic acid | C12H24O3 | [M-H]- | 215.1653 | 216.1713 | 4.68 | 17.8 | 1.25 | ↓ | ↓ | 
| 9   | Ferulic acid | C10H10O4 | [M-H]- | 193.0506 | 194.0558 | 5.21 | 11.46 | 1.22 | ↓ | ↓ | 
| 10  | Testosterone glucuronide | C22H32O6 | [M-H]- | 465.2483 | 466.2409 | 2.17 | 17.64 | 1.52 | ↓ | ↓ | 
| 11  | 1,2-Dipalmitoylphosphatidylglycerol | C38H75O10P | [M+H]+ | 723.5171 | 744.4980 | 2.90 | 20.67 | 1.52 | ↓ | ↓ | 
| 12  | N-Formylmethionine | C6H11NO3S | [M-H]- | 209.0921 | 208.0844 | 4.82 | 2.84 | 1.41 | ↓ | ↓ | 
| 13  | 4-Methylhippuric acid | C9H11NO3 | [M-H]- | 333.1656 | 332.1624 | 3.01 | 16.49 | 1.37 | ↓ | ↓ | 
| 14  | N-Isobutyrylglycine | C6H11NO3 | [M-H]- | 162.1125 | 161.1047 | 6.22 | 1.13 | 1.35 | ↓ | ↓ | 
| 15  | Phenylalanine | C9H11NO2 | [M-H]- | 166.0863 | 165.0786 | 6.07 | 3.24 | 1.34 | ↓ | ↓ | 
| 16  | 12-Hydroxydecanedioic acid | C12H24O3 | [M-H]- | 194.0812 | 193.0735 | 5.19 | 6.20 | 1.34 | ↓ | ↓ | 
| 17  | Phenylalanine | C9H11NO2 | [M-H]- | 180.0655 | 179.0582 | 5.59 | 5.78 | 1.32 | ↓ | ↓ | 
| 18  | Phenylacetylglycine | C10H11NO3 | [M-H]- | 142.0662 | 143.0733 | 7.09 | 5.12 | 1.29 | ↓ | ↓ | 
| 19  | 3-Hydroxybutyric acid | C4H8O3 | [M-H]- | 132.0768 | 131.0694 | 7.63 | 1.77 | 1.05 | ↓ | ↓ | 
| 20  | 3-Hydroxyanthranilic acid | C7H7NO3 | [M-H]- | 154.0499 | 153.0427 | 6.54 | 1.13 | 1.06 | ↓ | ↓ | 
| 21  | Creatine | C4H9N3O2 | [M-H]+ | 318.3003 | 317.2921 | 3.17 | 18.86 | 1.10 | ↓ | ↓ | 
| 22  | 2-Amino-1,3,4-octadecanetriol | C18H39NO3 | [M-H]+ | 169.0972 | 168.0872 | 5.97 | 1.45 | 1.07 | ↓ | ↓ | 
| 23  | 3-Hydroxyanthranilic acid | C7H7NO3 | [M-H]+ | 154.0499 | 153.0427 | 6.54 | 1.13 | 1.06 | ↓ | ↓ | 
| 24  | Pyridoxamine | C8H12N2O2 | [M+H]+ | 1.09 | 1.13 | 1.45 | 1.07 | ↓ | ↓ | 
| 25  | Pyridoxal | C8H9NO3 | [M+H]+ | 168.0655 | 167.0581 | 5.99 | 1.78 | 1.09 | ↓ | ↓ | 
| 26  | Pyridoxal | C8H9NO3 | [M+H]+ | 162.0662 | 163.0733 | 7.09 | 5.12 | 1.29 | ↓ | ↓ |
are able to form vitamin B6; consequently, these are key pathways were shown to interact with each other to form a tryptophan. The metabolites involved in these metabolic phenylalanine, and the biosynthesis of both tyrosine and Mooney, 2010) metabolism, phenylalanine metabolism, of TBD-treated-PMOP, including vitamin B6 (Hellmann and related to individual differences among the rats. It is likely that this observation was investigated the relative effects of different TBD doses on OVX rats; doses were selected according to the guiding principles laid down by non-clinical pharmacokinetic drug research. The metabolic status of phenylalanine is closely related to normal physiological function in the body. Previous researchers (Tao et al., 2017) have highlighted that the regulation of metabolic disorders associated with phenylalanine can prevent the occurrence of osteoporosis. Hippuric acid, a glycine conjugate of benzoic acid, is expressed in many disorders associated with enzymatic metabolism, including diabetes, obesity, and osteoporosis. Hippuric acid is mainly excreted via glomerular filtration and by an active secretion mechanism in the renal tubules. However, when the kidney is damaged, the content of hippuric acid in the urine decreases; consequently, there is an increase in the serum levels of hippuric acid (Wang and Bao, 2013). Vitamin D needs to be catalyzed by 1α-hydroxylase in the kidney and is then hydroxylated again to become the more active 1,25-(OH)2D3. A reduction in 1,25-(OH)2D3 content will inevitably lead to the loss of bone mass and induce osteoporosis in the bones (Lin et al., 2008).

CYP19A1, an aromatase-encoding gene, is known to be related to osteoporosis and can influence BMD by altering the levels of estrogen (Sowers et al., 2006). HSD11B1 is known to be expressed by human osteoblasts in vivo and could reduce the proliferation of osteoblasts and induce the differentiation of osteoblasts in vitro. Gene polymorphism can result in direct changes in the mass of bone and can help to convert androgens and glucocorticoids to estrogen (Hwang et al., 2009). A previous study showed significant associations between a range of HSD11B1 alleles and haplotypes and bone fracture density and BMD in postmenopausal women. VDR is the target receptor that regulates the transcription of vitamin D. Previously, researchers
have focused on the relationship between VDR and PMOP and demonstrated that changes in the VDR genotype were evident in patients with PMOP (Zhang L. et al., 2018). We found that the levels of these indices in the OVX group were much higher than those in the sham group, but were down regulated in the drug-treatment groups, thus suggesting that TBD can treat PMOP by regulating the specific levels of these targets.

Previous literature has reported a clear relationship between vitamin B6 levels, vitamin D, and parathyroid hormone (PTH) (Khundmiri et al., 2016), and a positive correlation between VDR, PTH, and vitamin D. This view makes the results of network pharmacology and metabolomics organically combined. Phyridoxine and pyridoxal are two forms of vitamin B6, which are important different metabolites in the vitamin B6 metabolic pathway (Saito, 2006). In other words, there is a close connection between the gene VDR and the differential metabolites compound phyridoxine, pyridoxal, and the vitamin B6 metabolic pathway. We used network pharmacology and metabolomics to integrate the crucial targets, differential metabolite and metabolic pathways to explore the mechanism of TBD to treat PMOP. Our analysis showed that VDR and vitamin B6 metabolism were critical mechanisms underlying the effect of TBD on PMOP. However, we have not been able to identify the specific components of TBD that combine with the target VDR. In our future research, we aim to use online docking software in an attempt to identify the specific compounds in TBD that bind to VDR; such work should provide us with stronger evidence for the wider application of TBD in the clinical treatment of PMOP.

CONCLUSION

By integrating the results derived from network pharmacology and metabolomics, we identified VDR and vitamin B6 metabolism as the key indicator and pathway, respectively, for the action of TBD against PMOP. ELISAs further showed that several crucial targets (VDR, HSD11B1, and CYP19A1) were elevated in the OVX group but were reduced following TBD treatment. From a mechanistic point of view, TBD appears to regulate vitamin B6 metabolism by altering VDR content, thus mitigating the process of PMOP. Our findings enhance our understanding of how TBD could be used to treat PMOP and will help to facilitate the wider clinical use of TBD treatments.

REFERENCES

Alexandre, C., and Vico, L. (2011). Pathophysiology of bone loss in disuse osteoporosis. Joint Bone Spine 78, 572–576. doi: 10.1016/j.jbspin.2011.04.007
Fernstrom, J. D., and Fernstrom, M. H. (2007). Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain. J. Nutr. 137, 1539S–1547S. doi: 10.1093/jn/137.6.1539S
Gambacciani, M., Cagnacci, A., and Lello, S. (2019). Hormone replacement therapy and prevention of chronic conditions. Climacteric 22, 303–306. doi: 10.1080/13697137.2018.1551347
Gefeller, D., Groudidier, A., Wirth, M., Daina, A., Michielin, O., and Zoete, V. (2014). SwissTargetPrediction: a web server for target prediction of bioactive small molecules. Nucleic Acids Res. 42, W32–W38. doi: 10.1093/nar/gku293

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.

ETHICS STATEMENT

The animal study was reviewed and approved by Animal Ethics Committee of Inner Mongolia Medical University (Reference: SCXK2015-0001).

AUTHOR CONTRIBUTIONS

PX conceived of and designed the experiments. FY performed the experiment and carried out the animal experiments. XD performed the data analysis and wrote the paper. PX gave some advice. JL, FM, JKL, CL, and RB collected Echinops latifolius Tausch samples outside. FY and XD conducted the data interpretation. All authors contributed to the article and approved the submitted version.

FUNDING

This work was financially supported by National Natural Science Foundation of China (81860756), National Natural Science Foundation of China (81960758), Natural Science Foundation of Inner Mongolia Autonomous Region (2017MS08122), Natural Science Foundation of Inner Mongolia Autonomous Region (2019MS08111), Inner Mongolia Science and Technology Innovation Guide Project (02039001), Inner Mongolia Autonomous Region Higher Education Science Research Project (NJZY19099).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2020.581991/full#supplementary-material

Guo, S., Liu, J., Li, N., Ma, F. X., Gao, J. P., Xue, P. F., et al. (2020). Evaluation of the Possibility of Eucommia ulmoides Leaves Replacing its Barks by Fingerprint combined with multi-components Quantitative by One Marker Method. J. Chin. Med. Mater. 4, 898–904. doi: 10.13863/j.issn1001-4454.2020.04.022
Han, D., Chen, W., Gu, X., Shan, R., Zou, J., Liu, G., et al. (2017). Cytoprotective effect of chlorogenic acid against hydrogen peroxide-induced oxidative stress in MC3T3-E1 cells through PI3K/Akt-mediated Nrf2/HO-1 signaling pathway. Oncotarget 8, 14680–14692. doi: 10.18632/oncotarget.14747
Hao, D., and Xiao, P. G. (2014). Network pharmacology; a Rosetta Stone for traditional Chinese medicine. Drug Dev. Res. 75, 299–312. doi: 10.1002/ddr.21214
Hellmann, H., and Mooney, S. (2010). Vitamin B6; a molecule for human health? Molecules 15, 442–459. doi: 10.3390/molecules15010442
